Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression

Li, Haocheng; Han, Song; Sun, Qingfeng; Yao, Ye; Li, Shiyong; Yuan, Chao; Zhang, Bo; Bao, Ji; Wu, Jia Qian; Song, Yanshuang; Wang, Haiyang

doi:10.18632/aging.101863

Cited by 54 publications

(35 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was suggested that ANRIL could promote cholesterol efflux and inhibit inflammatory cytokines such as IL-1β and TNF-α in ox-LDL-exposed THP-1 macrophages by silencing ADAM (a disintegrin and metalloprotease) 10 (66). ADAMs participated in a variety of metabolic and inflammatory conditions including atherosclerosis, neuro-inflammatory response, and acute lung inflammation (66). In colorectal cancer, ANRIL could sponge miR-Let-7a to enhance the expression of ATP binding cassette subfamily C member 1 (ABCC1), which promotes cholesterol efflux and inhibits inflammation in vivo (100).…”

Section: Anril (Cdkn2b-as1)mentioning

confidence: 99%

Long Non-Coding RNAs Link Oxidized Low-Density Lipoprotein With the Inflammatory Response of Macrophages in Atherogenesis

Yan

Song

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

Atherosclerosis is characterized as a chronic inflammatory response to cholesterol deposition in arteries. Low-density lipoprotein (LDL), especially the oxidized form (ox-LDL), plays a crucial role in the occurrence and development of atherosclerosis by inducing endothelial cell (EC) dysfunction, attracting monocyte-derived macrophages, and promoting chronic inflammation. However, the mechanisms linking cholesterol accumulation with inflammation in macrophage foam cells are poorly understood. Long non-coding RNAs (lncRNAs) are a group of non-protein-coding RNAs longer than 200 nucleotides and are found to regulate the progress of atherosclerosis. Recently, many lncRNAs interfering with cholesterol deposition or inflammation were identified, which might help elucidate their underlying molecular mechanism or be used as novel therapeutic targets. In this review, we summarize and highlight the role of lncRNAs linking cholesterol (mainly ox-LDL) accumulation with inflammation in macrophages during the process of atherosclerosis.

show abstract

Section: Anril (Cdkn2b-as1)mentioning

confidence: 99%

Long Non-Coding RNAs Link Oxidized Low-Density Lipoprotein With the Inflammatory Response of Macrophages in Atherogenesis

Yan

Song

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Long noncoding RNAs (lncRNAs) are a category of promising noncoding RNAs that have been found to interplay with multiple factors in various diseases, which are characterized by a length more than 200 nt and almost no protein‐coding function . However, although lncRNAs are not involved in protein coding, these molecules are able to mediate gene levels at different aspects, including transcription, post‐transcription processing, and so on .…”

Section: Introductionmentioning

confidence: 99%

Potential role of circulating long noncoding RNA MALAT1 in predicting disease risk, severity, and patients' survival in sepsis

Geng

Liu

2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background This study aimed to investigate the plasma long noncoding RNA metastasis‐associated lung adenocarcinoma transcript 1 (lncRNA MALAT1) expression with risk, severity, inflammation level, and prognosis in sepsis. Methods One hundred and ninety sepsis patients and 190 health controls (HCs) were consecutively recruited. Blood samples within 24 hours after admission of sepsis patients and those on enrollment of HCs were collected, and then, plasma was separated for lncRNA MALAT1 and miR‐125b expressions detections by RT‐qPCR. In sepsis patients, clinical data and 28‐day mortality were recorded, and plasma inflammatory cytokines expressions were detected by ELISA. Results Plasma lncRNA MALAT1 expression was elevated in sepsis patients than HCs (P < 0.001), and ROC curve disclosed that it had a good value in predicting sepsis risk with an area under curve (AUC) of 0.823 (95% CI: 0.783‐0.864). Additionally, lncRNA MALAT1 expression was positively correlated with Scr (P = 0.005), WBC (P = 0.017), CRP (P < 0.001), PCT (P < 0.001), TNF‐α (P < 0.001), IL‐8 (P < 0.001), IL‐17 (P = 0.001), APACHE II score (P < 0.001), and SOFA score (P < 0.001). LncRNA MALA1 expression was elevated in deaths compared with survivors (P < 0.001) and could predict the risk of 28‐day mortality with an AUC of 0.755 (95% CI: 0.682‐0.828). Accumulating survival was worse in patients with lncRNA MALAT1 high expression compared with patients who had lncRNA MALAT1 low expression (P < 0.001). Moreover, lncRNA MALAT1 expression was negatively correlated with miR‐125b level in both sepsis patients (P < 0.001) and HCs (P < 0.001). Conclusion LncRNA MALAT1 could be developed as a potential biomarker for facilitating diagnosis and management in sepsis patients.

show abstract

“…In line, cholesterol efflux was increased in LXR-stimulated MeXis-expressing RAW cells, while lack of MeXis in bone marrow (BM) cells of WD-fed Ldlr −/− mice accelerated atherosclerosis progression measured as lesion size and lipid content, compared with wild-type BM. LncRNA ANRIL (antisense non coding RNA in the INK4 locus) was reported to promote cholesterol efflux [39]. Mechanistically, ANRIL can function as scaffold lncRNA by recruiting DNA methyltransferase 1 (DNMT1) to the ADAM10 promoter, enhancing its methylation.…”

Section: Lncrna-protein Interactions In Atherosclerosismentioning

confidence: 99%

The Long Non-coding Road to Atherosclerosis

Josefs

Boon

2020

Curr Atheroscler Rep

View full text Add to dashboard Cite

Purpose of Review To summarize recent insights into long non-coding RNAs (lncRNAs) involved in atherosclerosis. Because atherosclerosis is the main underlying pathology of cardiovascular diseases (CVD), the world's deadliest disease, finding novel therapeutic strategies is of high interest. Recent Findings LncRNAs can bind to proteins, DNA, and RNA regulating disease initiation and plaque growth as well as plaque stability in different cell types such as endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and macrophages. A number of lncRNAs have been implicated in cholesterol homeostasis and foam cell formation such as LASER, LeXis, and CHROME. Among others, MANTIS, lncRNA-CCL2, and MALAT1 were shown to be involved in vascular inflammation. Further regulations include, but are not limited to, DNA damage response in ECs, phenotypic switch of VSMCs, and various cell death mechanisms. Interestingly, some lncRNAs are closely correlated with response to statin treatment, such as NEXN-AS1 or LASER. Additionally, some lncRNAs may serve as CVD biomarkers. Summary LncRNAs are a potential novel therapeutic target to treat CVD, but research of lncRNA in atherosclerosis is still in its infancy. With increasing knowledge of the complex and diverse regulations of lncRNAs in the heterogeneous environment of atherosclerotic plaques, lncRNAs hold promise for their clinical translation in the near future.

show abstract

Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression

Cited by 54 publications

References 49 publications

Long Non-Coding RNAs Link Oxidized Low-Density Lipoprotein With the Inflammatory Response of Macrophages in Atherogenesis

Long Non-Coding RNAs Link Oxidized Low-Density Lipoprotein With the Inflammatory Response of Macrophages in Atherogenesis

Potential role of circulating long noncoding RNA MALAT1 in predicting disease risk, severity, and patients' survival in sepsis

The Long Non-coding Road to Atherosclerosis

Contact Info

Product

Resources

About